reports
- ABGSC Metals & Mining Research
- Adrian Gilani
Elliptic Labs Shipping Its AI Software Platform on Lenovo’s Newest Thi...
OSLO, Norway--(BUSINESS WIRE)-- (OSE:), a global AI software company and the world leader in AI Virtual Smart Sensors™, is now shipping its 100% software-only AI Virtual Human Presence Sensor on four select models of latest generation ThinkPad P Series workstation laptops — ThinkPad P1 Gen 7, P16v i Gen 2, P16s i Gen 3, and P14s i Gen 5. Elliptic Labs’ partner sits at these laptops’ core with its latest generation . Elliptic Labs announced the contract preceding this launch . Elliptic Labs’ AI Virtual Smart Sensor Platform™ leverages the company’s ultrasound, AI, and sensor fusion experti...
Galderma Delivers a Strong Start to the Year With Record Net Sales of ...
ZUG, Switzerland--(BUSINESS WIRE)-- Galderma Group AG (SWX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2024. Record net sales of 1.071 billion USD in the first quarter of 2024, surpassing for the first time the 1 billion USD mark for the first three months in a year Net sales growth for the first quarter of 2024 was 12.4% year-on-year on a constant currency basis1, primarily driven by volume Broad-based growth across all product categories, with constant currency year-on-year growth of 19.3% for Injectable Aesthetics...
CARMAT annonce ses résultats annuels 2023 et fait un point sur ses ava...
PARIS--(BUSINESS WIRE)-- Regulatory News: CARMAT (FR0010907956, ALCAR, éligible PEA-PME), concepteur et développeur du cœur artificiel total le plus avancé au monde (la « Société » ou « CARMAT »), visant à offrir une alternative thérapeutique aux malades souffrant d’insuffisance cardiaque biventriculaire avancée, annonce aujourd’hui ses résultats annuels pour l’exercice clos au 31 décembre 2023 et fait un point sur ses avancées et perspectives 2024. Les comptes annuels ont été arrêtés par le conseil d’administration le 22 avril 2024, sur la base du principe de continuité d’exploitation. La...
WithSecure Interim report 1 January – 31 March 2024: Elements Company ...
WithSecure Interim report 1 January – 31 March 2024: Elements Company profitability developing positively, despite slow start of the year WithSecure Corporation, Interim report release 1 January – 31 March 2024, 24 April 2024 at 8.00 EEST WithSecure Interim report 1 January – 31 March 2024: Elements Company profitability developing positively, despite slow start of the year Highlights of January – March 2024 (“first quarter”) Annual Recurring Revenue (ARR) (1) for Elements Cloud (2) increased by 10% to EUR 80.5 million (EUR 73.4 million)Elements Cloud ARR increase from previous quar...
WithSecuren osavuosikatsaus 1.1. – 31.3.2024: Elements-yhtiön kannatta...
WithSecuren osavuosikatsaus 1.1. – 31.3.2024: Elements-yhtiön kannattavuus kehittyy suotuisasti, huolimatta hitaasta vuoden aloituksesta WithSecure Oyj, Osavuosikatsaus 1.1. – 31.3.2024, 23.4.2024 klo 8.00 WithSecuren osavuosikatsaus 1.1. – 31.3.2024: Elements-yhtiön kannattavuus kehittyy suotuisasti, huolimatta hitaasta vuoden aloituksesta Keskeiset tapahtumat tammi-maaliskuussa 2024 ("ensimmäinen neljännes") Pilvipohjaisten Elements-tuotteiden ja palvelujen (1) jatkuva vuosilaskutus (Annual Recurring Revenue, ARR) (2) kasvoi 10 % ja oli 80,5 miljoona...
Pharming to be honored as Industry Innovator at National Organization...
Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact Awards Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disease state, APDS, was first characterized Leiden, the Netherlands, April 24, 2024: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is pleased to announce its recognition as an Industry Innovator by the National Organization for Rare Disorders (NORD®) at the Rare Impact Awards on June 8, 2024...
Vopak reports strong Q1 2024 results and increases FY 2024 outlook
Vopak reports strong Q1 2024 results and increases FY 2024 outlook The Netherlands, 24 April 2024 Vopak reports strong Q1 2024 results and increases FY 2024 outlook Key highlights Q1 2024 Improve Increased net profit -including exceptional items1- in Q1 2024 to EUR 106 million, an improvement of 3% year-on-year, driven by favorable storage demand across different geographies and marketsIncreased proportional EBITDA -excluding exceptional items1- in Q1 2024 to EUR 298 million, an improvement of 9% year-on-year when adjusted for divestment impacts of EUR 21 millionFurther strength...
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results an...
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates In-depth analysis of VIVIAD Phase 2b results is ongoing, including pre-specified and exploratory endpoints; findings to date are consistent with previously announced topline data observing no statistically significant or clinically meaningful effect of varoglutamstat on cognition and function in early AD up to 600mg twice a day (BID) doseStatistically sig...
Borregaard ASA: EBITDA1 of NOK 442 million in the 1st quarter
Borregaard ASA: EBITDA1 of NOK 442 million in the 1st quarter Borregaard’s operating revenues reached NOK 1,975 million (NOK 1,850 million)2 in the 1st quarter of 2024. EBITDA1 increased to NOK 442 million (NOK 435 million). The result in BioSolutions increased while results in BioMaterials and Fine Chemicals were lower compared with the 1st quarter of 2023. The result in BioSolutions increased due to higher sales volume and reduced energy costs. In BioMaterials, higher sales volume was more than offset by lower sales prices and higher wood costs. Fine Chemicals had a lower result due to l...
Reminder: Unifiedpost Group Strategy Update Presentation on 30 April 2...
Reminder: Unifiedpost Group Strategy Update Presentation on 30 April 2024 La Hulpe, Belgium – 24 April 2024, 7:00 a.m. CET – Unifiedpost Group SA (Euronext Brussels: UPG) (“Unifiedpost”), a leader in cloud-based business process solutions, will present an overview of its mid-term strategy on Tuesday, 30 April 2024.The event will take place from 2:00pm to 4:00pm CET on Tuesday, 30 April 2024. The presenting team will be Hans Leybaert, CEO, Koen De Brabander, CFO, and some of the group’s business leaders. The agenda for the day is as follows: Introductions Key objectives Business updat...
First quarter 2024 financial information: Good start to the year
First quarter 2024 financial information: Good start to the year Good start to the year _PRESS RELEASE_ First quarter 2024 standard sales of €1,692 million, up +2.8% organically year-on-year and up +4.7% excluding Other activitiesElectrification businesses up +6.7% organically, reflecting double digit growth in Generation & Transmission segment and an acceleration in electrification trends globally Record adjusted backlog for Generation & Transmission, mainly subsea-driven, at €6.7 billion, up +10.2% compared to December 2023Electrification Pure Player profile further strengthened ...
Information financière du premier trimestre 2024: Bon début d'année
Information financière du premier trimestre 2024: Bon début d'année Bon début d’année 2024 _COMMUNIQUÉ DE PRESSE_ Chiffre d’affaires standard de 1 692 millions d’euros au premier trimestre 2024, en croissance organique de +2,8 % par rapport à la même période de 2023 et de +4,7 % hors Autres activitésCroissance organique de +6,7 % des activités d'Electrification, reflétant une croissance à deux chiffres de l’activité Production d’énergie & Transmission et une accélération globale des tendances dans l'électrification Carnet de commandes ajusté record de 6,7 milliard...
BioSenic postpones its annual general meeting of the shareholders and ...
BioSenic postpones its annual general meeting of the shareholders and provides temporary non-audited financial figures for 2023 PRESS RELEASE - PRIVILEGED INFORMATION In view of the restructuring plan announced on April 11, 2024, BioSenic has decided to postpone the publication of its 2023 annual report as well as its annual general meeting of shareholders, so that the Enterprise Court of Nivelles can make a decision before the completion of the annual formalities. The Company believes that this postponement is preferable to ensure that the financial statements can be prepared on a going...
Ipsen delivers strong sales in the first quarter of 2024, driven by gr...
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. Q1 2024 Q1 2023 % change €m €m ActualCER1Growth platforms2509.7452.012.8%16.2%New medicines345.514.3n/an/aSomatuline®257.8263.2-2.0%-1.3%Other9.512.4-23.8%-20.5%Total Sales822.4741.910.9%13.3% Highlights Total-sales growth of 13.3% at CER1, or 10.9% as reported, driven by t...
Ipsen enregistre une solide croissance de ses ventes au premier trimes...
Ipsen enregistre une solide croissance de ses ventes au premier trimestre et confirme ses objectifs financiers pour l'exercice 2024 PARIS, FRANCE, 24 avril 2024 - Ipsen (Euronext : IPN ; ADR : IPSEY), groupe biopharmaceutique mondial de spécialité, publie aujourd’hui son chiffre d’affaires pour le premier trimestre 2024. Q1 2024 Q1 2023 % change €m €m Réalisé TTC1Plateforme de croissance2 509,7452,012,8%16,2%Nouveaux médicaments3 45,514,3n/an/aSomatuline® 257,8263,2-2,0%-1,3%Autres 9,512,4-23,8%-20,5%Chiffre d’affaires Groupe 822,4741,910.9%13.3% Faits marquants Croissance des ventes de...
Wereldhave Trading update Q1 2024
Wereldhave Trading update Q1 2024 Full Service Center footfall continues to power ahead: 10% above Q1 2023Retail sales +5%, well above inflationPolarizing leasing market in the Benelux with several expanding formulas but also some bankruptciesLeasing spreads in the Netherlands moving into positive territoryRent collection >97% underpinning tenant qualityLTV improved to 41.5% due to positive Belgian revaluations (ERV driven) and targeted CAPEXUpdate on short-term strategic focus: rotating capital out of the Netherlands to further reduce LTVFull Service Center Sterrenburg awarded with the 202...
Melexis Q1 2024 results – First quarter sales of 241.8 million EUR
Melexis Q1 2024 results – First quarter sales of 241.8 million EUR Regulated information Intermediate declaration by the Board of Directors Ieper, Belgium - April 24th, 2024, 07.00 hrs CET Dear, Please find herewith the link to our most recent press release: Attachment
Melexis Q1 2024 résultats – Chiffre d'affaires de 241.8 millions d'eur...
Melexis Q1 2024 résultats – Chiffre d'affaires de 241.8 millions d'euros au premier trimestre Information réglementée Déclaration intermédiaire par le Conseil d'administrationYpres, Belgique - le 24 avril 2024, 07.00 H. CET Veuillez trouver ici le lien vers notre dernier communiqué de presse: Pièce jointe
TGS Q1 2024 Presentation and Webcast
TGS Q1 2024 Presentation and Webcast OSLO, Norway (24 April 2024) - TGS will release its Q1 2024 results at approximately 07:00 CEST on 8 May 2024. CEO Kristian Johansen and CFO Sven Børre Larsen will present the results at 09:00 CEST at House of Oslo, Ruseløkkveien 34, Oslo, Norway. The presentation is open to the public and can be followed live online. Access and registration for online attendees are available by copying and pasting this link into your browser: The slides from the presentation will also be available in PDF format at both the TGS and Oslo Stock Exchange websites. For m...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.